Literature DB >> 18272844

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.

Liffert Vogt1, Femke Waanders, Frans Boomsma, Dick de Zeeuw, Gerjan Navis.   

Abstract

There is large interindividual variability in the antiproteinuric response to blockade of the renin-angiotensin-aldosterone system (RAAS). A low-sodium diet or addition of diuretics enhances the effects of RAAS blockade on proteinuria and BP, but the efficacy of the combination of these interventions is unknown. Therefore, this randomized, double-blind, placebo-controlled trial to determine the separate and combined effects of a low-sodium diet and hydrochlorothiazide (HCT) on proteinuria and BP was performed. In 34 proteinuric patients without diabetes, mean baseline proteinuria was 3.8 g/d, and this was reduced by 22% by a low-sodium diet alone. Losartan monotherapy reduced proteinuria by 30%, and the addition of a low-sodium diet led to a total reduction by 55% and the addition of HCT to 56%. The combined addition of HCT and a low-sodium diet reduced proteinuria by 70% from baseline (all P < 0.05). Reductions in mean arterial pressure showed a similar pattern (all P < 0.05). In addition, individuals who did not demonstrate an antiproteinuric response to losartan monotherapy did respond when a low-sodium diet or a diuretic was added. In conclusion, a low-sodium diet and HCT are equally efficacious in reducing proteinuria and BP when added to a regimen containing losartan and especially seem to benefit individuals who are resistant to RAAS blockade. Combining these interventions in sodium status is an effective method to maximize the antiproteinuric efficacy of RAAS blockade.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272844      PMCID: PMC2386733          DOI: 10.1681/ASN.2007060693

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  37 in total

1.  Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease.

Authors:  A Chrysostomou; G Becker
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients.

Authors:  J D Kopple
Journal:  Am J Kidney Dis       Date:  2001-10       Impact factor: 8.860

3.  Effectiveness of aldosterone blockade in patients with diabetic nephropathy.

Authors:  Atsuhisa Sato; Koichi Hayashi; Mitsuhide Naruse; Takao Saruta
Journal:  Hypertension       Date:  2003-01       Impact factor: 10.190

4.  A low-sodium diet potentiates the effects of losartan in type 2 diabetes.

Authors:  Christine A Houlihan; Terri J Allen; Amynta L Baxter; Sianna Panangiotopoulos; David J Casley; Mark E Cooper; George Jerums
Journal:  Diabetes Care       Date:  2002-04       Impact factor: 19.112

Review 5.  Progression, remission, regression of chronic renal diseases.

Authors:  P Ruggenenti; A Schieppati; G Remuzzi
Journal:  Lancet       Date:  2001-05-19       Impact factor: 79.321

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin.

Authors:  Genevieve Nguyen; Françoise Delarue; Céline Burcklé; Latifa Bouzhir; Thomas Giller; Jean-Daniel Sraer
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

8.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321

9.  A role for uric acid in the progression of renal disease.

Authors:  Duk-Hee Kang; Takahiko Nakagawa; Lili Feng; Susumu Watanabe; Lin Han; Marilda Mazzali; Luan Truong; Raymond Harris; Richard J Johnson
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

10.  Renin-stimulated TGF-beta1 expression is regulated by a mitogen-activated protein kinase in mesangial cells.

Authors:  Y Huang; N A Noble; J Zhang; C Xu; W A Border
Journal:  Kidney Int       Date:  2007-03-28       Impact factor: 18.998

View more
  98 in total

1.  Diverse diuretics regimens differentially enhance the antialbuminuric effect of renin-angiotensin blockers in patients with chronic kidney disease.

Authors:  Enrique Morales; Jara Caro; Eduardo Gutierrez; Angel Sevillano; Pilar Auñón; Cristina Fernandez; Manuel Praga
Journal:  Kidney Int       Date:  2015-08-26       Impact factor: 10.612

2.  Relapse or worsening of nephrotic syndrome in idiopathic membranous nephropathy can occur even though the glomerular immune deposits have been eradicated.

Authors:  Chadwick E Barnes; William A Wilmer; Raul A Hernandez; Christopher Valentine; Leena S Hiremath; Tibor Nadasdy; Anjali A Satoskar; Rose L Shim; Brad H Rovin; Lee A Hebert
Journal:  Nephron Clin Pract       Date:  2011-07-08

3.  A randomized trial of dietary sodium restriction in CKD.

Authors:  Emma J McMahon; Judith D Bauer; Carmel M Hawley; Nicole M Isbel; Michael Stowasser; David W Johnson; Katrina L Campbell
Journal:  J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 10.121

Review 4.  World Kidney Day 2011: protect your kidneys, save your heart.

Authors:  William G Couser; Miguel C Riella
Journal:  Pediatr Nephrol       Date:  2011-01-20       Impact factor: 3.714

5.  The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

Authors:  Bauke Schievink; Dick de Zeeuw; Hans-Henrik Parving; Peter Rossing; Hiddo Jan Lambers Heerspink
Journal:  Br J Clin Pharmacol       Date:  2015-05-28       Impact factor: 4.335

6.  [Salt restriction in people with hypertension and patients with cardiovascular disease : meaningfulness and extent].

Authors:  J Hoyer
Journal:  Internist (Berl)       Date:  2015-07       Impact factor: 0.743

7.  Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.

Authors:  Femke Waanders; Vishal S Vaidya; Harry van Goor; Henri Leuvenink; Kevin Damman; Inge Hamming; Joseph V Bonventre; Liffert Vogt; Gerjan Navis
Journal:  Am J Kidney Dis       Date:  2008-09-27       Impact factor: 8.860

8.  Effects of salt supplementation on the albuminuric response to telmisartan with or without hydrochlorothiazide therapy in hypertensive patients with type 2 diabetes are modulated by habitual dietary salt intake.

Authors:  Elif I Ekinci; Georgina Thomas; David Thomas; Cameron Johnson; Richard J Macisaac; Christine A Houlihan; Sue Finch; Sianna Panagiotopoulos; Chris O'Callaghan; George Jerums
Journal:  Diabetes Care       Date:  2009-06-23       Impact factor: 17.152

Review 9.  The effect of RAAS blockade on the progression of diabetic nephropathy.

Authors:  Sara S Roscioni; Hiddo J Lambers Heerspink; Dick de Zeeuw
Journal:  Nat Rev Nephrol       Date:  2013-12-03       Impact factor: 28.314

10.  Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort study.

Authors:  Matthew R Weir; Raymond R Townsend; Jeffrey C Fink; Valerie Teal; Stephen M Sozio; Cheryl A Anderson; Lawrence J Appel; Sharon Turban; Jing Chen; Jiang He; Natasha Litbarg; Akinlolu Ojo; Mahboob Rahman; Leigh Rosen; Susan Steigerwalt; Louise Strauss; Marshall M Joffe
Journal:  Am J Nephrol       Date:  2012-10-12       Impact factor: 3.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.